CN111329044A - Composition for recovering patients with liver diseases - Google Patents
Composition for recovering patients with liver diseases Download PDFInfo
- Publication number
- CN111329044A CN111329044A CN202010112209.2A CN202010112209A CN111329044A CN 111329044 A CN111329044 A CN 111329044A CN 202010112209 A CN202010112209 A CN 202010112209A CN 111329044 A CN111329044 A CN 111329044A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- parts
- powder
- maltodextrin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 208000019423 liver disease Diseases 0.000 title claims abstract description 23
- 229940088594 vitamin Drugs 0.000 claims abstract description 56
- 229930003231 vitamin Natural products 0.000 claims abstract description 56
- 235000013343 vitamin Nutrition 0.000 claims abstract description 56
- 239000011782 vitamin Substances 0.000 claims abstract description 56
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 45
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 45
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 45
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 42
- 229940013618 stevioside Drugs 0.000 claims abstract description 42
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 42
- 235000019202 steviosides Nutrition 0.000 claims abstract description 42
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 33
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 33
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 33
- 239000011707 mineral Substances 0.000 claims abstract description 33
- 235000021119 whey protein Nutrition 0.000 claims abstract description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 29
- 239000008158 vegetable oil Substances 0.000 claims abstract description 29
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 22
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 22
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000004475 Arginine Substances 0.000 claims abstract description 21
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 14
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 8
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 5
- 239000003765 sweetening agent Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 48
- 238000002156 mixing Methods 0.000 claims description 42
- -1 compound vitamin Chemical class 0.000 claims description 36
- 239000011812 mixed powder Substances 0.000 claims description 32
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 16
- 239000003085 diluting agent Substances 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 16
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 11
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 11
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 11
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- 239000011719 vitamin A Substances 0.000 claims description 11
- 235000019155 vitamin A Nutrition 0.000 claims description 11
- 229940045997 vitamin a Drugs 0.000 claims description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 10
- 208000002720 Malnutrition Diseases 0.000 claims description 10
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 10
- 229930003316 Vitamin D Natural products 0.000 claims description 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 10
- 229930003427 Vitamin E Natural products 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 10
- 239000011777 magnesium Substances 0.000 claims description 10
- 229910052749 magnesium Inorganic materials 0.000 claims description 10
- 235000000824 malnutrition Nutrition 0.000 claims description 10
- 230000001071 malnutrition Effects 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 10
- 239000011669 selenium Substances 0.000 claims description 10
- 229910052711 selenium Inorganic materials 0.000 claims description 10
- 239000011710 vitamin D Substances 0.000 claims description 10
- 235000019166 vitamin D Nutrition 0.000 claims description 10
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 10
- 239000011709 vitamin E Substances 0.000 claims description 10
- 235000019165 vitamin E Nutrition 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 229930003448 Vitamin K Natural products 0.000 claims description 9
- 239000011651 chromium Substances 0.000 claims description 9
- 229910052804 chromium Inorganic materials 0.000 claims description 9
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 9
- 239000011591 potassium Substances 0.000 claims description 9
- 229910052700 potassium Inorganic materials 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- 235000019168 vitamin K Nutrition 0.000 claims description 9
- 239000011712 vitamin K Substances 0.000 claims description 9
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 9
- 229940046008 vitamin d Drugs 0.000 claims description 9
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 229910052802 copper Inorganic materials 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 8
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 8
- 239000011664 nicotinic acid Substances 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 229940055726 pantothenic acid Drugs 0.000 claims description 8
- 235000019161 pantothenic acid Nutrition 0.000 claims description 8
- 239000011713 pantothenic acid Substances 0.000 claims description 8
- 239000011574 phosphorus Substances 0.000 claims description 8
- 229910052698 phosphorus Inorganic materials 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229960003080 taurine Drugs 0.000 claims description 8
- 239000011715 vitamin B12 Substances 0.000 claims description 8
- 239000011716 vitamin B2 Substances 0.000 claims description 8
- 239000011726 vitamin B6 Substances 0.000 claims description 8
- 229940046010 vitamin k Drugs 0.000 claims description 8
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 7
- 239000011691 vitamin B1 Substances 0.000 claims description 7
- 235000019482 Palm oil Nutrition 0.000 claims description 4
- 239000000944 linseed oil Substances 0.000 claims description 4
- 235000021388 linseed oil Nutrition 0.000 claims description 4
- 239000002540 palm oil Substances 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims 1
- 235000019519 canola oil Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 235000016709 nutrition Nutrition 0.000 abstract description 15
- 206010067125 Liver injury Diseases 0.000 abstract description 13
- 231100000753 hepatic injury Toxicity 0.000 abstract description 12
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 9
- 230000035764 nutrition Effects 0.000 abstract description 7
- 239000013589 supplement Substances 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 3
- 235000010755 mineral Nutrition 0.000 description 28
- 241000700159 Rattus Species 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 235000004554 glutamine Nutrition 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical group Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 6
- 235000019484 Rapeseed oil Nutrition 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000002672 hepatitis B Diseases 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 150000005693 branched-chain amino acids Chemical class 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229960002827 pioglitazone hydrochloride Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000020238 sunflower seed Nutrition 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 208000007386 hepatic encephalopathy Diseases 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006154 Chronic hepatitis C Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000018770 reduced food intake Nutrition 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a composition for recovering patients with liver diseases, which comprises the following raw materials: whey protein, vegetable oil, maltodextrin, galacto-oligosaccharide, arginine, glutamine, compound mineral substances, compound vitamins and sweetener stevioside. The applicant obtains a basic nutritional composition meeting the requirements of patients with liver diseases through multiple clinical researches, the composition can not only supplement the nutrition of the patients with liver diseases, but also has a good protection effect on liver injury, and further researches show that the composition has a good improvement effect on the patients with liver injury and diabetes mellitus.
Description
Technical Field
The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a composition for recovering patients with liver diseases.
Background
Liver diseases are common diseases and frequently encountered diseases in China, and can be generally divided into viral hepatitis, alcoholic liver diseases, drug-induced liver injury, fatty liver, liver cirrhosis, liver cancer and the like. The '2017 world hepatitis report' issued by world health organization of 21/4/2017 shows that about 3.25 million people are infected with chronic hepatitis B virus or hepatitis C virus worldwide. 2016 liver disease research report states that chronic hepatitis B causes over 33 million cancer-related deaths each year in China. The incidence of hepatitis C is second to that of hepatitis B, and accounts for 17.06 percent of the total incidence of viral hepatitis. The incidence of 'rich and noble diseases' such as alcoholic liver, fatty liver and the like is also improved year by year, and by the end of 2010, the incidence of the total non-alcoholic fatty liver disease in China is about 15%, the incidence of the non-alcoholic fatty liver disease in the first-line city is close to the developed country in the west and reaches 20% -30%, and the incidence of the fatty liver disease in the severely obese people reaches 61% -94%. According to the calculation, at least 2 hundred million people have fatty liver disease in China, and the number of people who convert fatty liver disease into hepatic fibrosis and hepatic cirrhosis is about 400-. The situation of alcoholic liver disease is very severe and can not be ignored, and by 2011, the conservative estimation is that the number of patients suffering from alcoholic liver disease in China is about 5000 ten thousand.
The liver, the most important substance in the body and the energy metabolism organ, plays an important role in the metabolism of sugar, lipid, protein, amino acid, vitamin, hormone and other substances. When liver is damaged by various reasons (viruses, alcohol, etc.), the energy metabolism of the body can be obviously changed. Therefore, patients with liver diseases are very likely to suffer from malnutrition. Ismail et al found in a 400-patient control study that Chronic Hepatitis C (CHC) patients had malnutrition prior to the development of cirrhosis. Mengqinghua et al found in the REE study of 142 Chronic Hepatitis B (CHB) patients: the incidence of malnutrition in CHB patients was 14.10%, with 15.49% of patients being hypermetabolized, 47.18% being normal, and 37.32% being hypometabolized. In the cirrhosis compensation phase, up to 50-80% of patients are complicated by malnutrition of different degrees. In the decompensation phase of cirrhosis, nearly 100% of patients are complicated by malnutrition. The causes of malnutrition in patients with liver disease include reduced food intake, reduced nutrient absorption, increased nutrient loss, high metabolic state, and insufficient synthesis. The degree of malnutrition in patients with liver disease directly affects the prognosis of the patient.
Therefore, the nutritional support is an important part of the comprehensive treatment of patients with liver diseases, and under the condition of ensuring that the carbohydrate is ingested to supply enough calories, the chronic hepatitis patients should be rich in protein and proper amount of fat, and simultaneously should not neglect to supplement proper amount of B vitamins and fat-soluble vitamins such as vitamin A, D, E and trace elements of calcium, magnesium, zinc, selenium and the like so as to supplement the loss of the trace nutrients caused by the damage of liver cells. Patients with liver cirrhosis, the European society for intestinal and intestinal nutrition (ESPEN) and the American society for intestinal and intestinal nutrition (ASPEN) both recommend a dietary intake pattern of few meals and more meals, preferably 4 to 6 meals per day. The energy intake standard is 35-40 kcal/kg/d), and the protein intake is 1.2-1.5 kcal/kg/d). For patients with liver failure, the protein is not suitable to be used as an energy supply substance, and is suitable to be used as a source supplement of a liver tissue repair substance, and the supply amount is 1.5-2.0 g/kg/d); 0.8-1.5 g/kg/d) of amino acid, and in severe hepatic encephalopathy, the branched chain amino acid is supplemented into veins, and the changes of indexes such as blood ammonia and the like are closely monitored, so that the nutrition supply scheme is adjusted at any time. Proper amount of B vitamins, vitamin A, C, D, E, K and minerals such as potassium, magnesium, calcium, zinc, phosphate, etc.
At present, the number of enteral nutrition products for patients with liver diseases in China is very small, and the patients with critical liver diseases are often accompanied by complications such as nephropathy and diabetes, and the enteral nutrition products are not considered in the formula of the existing products.
Disclosure of Invention
Based on the reasons, the applicant obtains a basic nutritional composition meeting the requirements of patients with liver diseases through multiple clinical researches, the composition can not only supplement the nutrition of the patients with liver diseases, but also has a good protection effect on liver injury, and further researches find that the composition also has a good improvement effect on the patients with liver injury and diabetes.
The special medical food of the invention is taken alone or in combination with other foods under the guidance of doctors or clinical dieticians. Is a formula food specially processed and prepared for meeting the special requirements of people with limited food intake, digestive absorption disorder, metabolic disorder or specific disease states on nutrients or diet. The special medical food is not a medicine, but is not a common food eaten by normal people, but is a formula food which is specially developed and produced according to scientific objective facts after a great deal of medical research of clinicians and nutriologists. When the target population cannot eat common diet or cannot meet the nutritional requirements of the target population with daily diet, the formula food for special medical purposes can be used as a nutritional supplement way to play a nutritional support role. The food cannot replace the therapeutic effect of the drug, and the product must not claim the prevention and treatment function of the disease.
The invention is realized by the following technical scheme.
The composition comprises the following raw materials in parts by weight: 20-30 parts of whey protein, 10-30 parts of vegetable oil, 40-60 parts of maltodextrin, 0.1-3 parts of galacto-oligosaccharide, 0.1-2 parts of arginine, 0.1-2 parts of glutamine, 2.8-4.2 parts of compound mineral, 0.28-0.42 part of compound vitamin and 0.01-0.1 part of sweetening agent stevioside.
The compound vitamin comprises vitamin A, vitamin D, vitamin E, vitamin K, and vitamin B1Vitamin B2Vitamin B6Vitamin B12Nicotinic acid, folic acid, pantothenic acid, vitamin C biotin and taurine.
The compound mineral comprises sodium, potassium, copper, magnesium, ferrum, zinc, manganese, calcium, phosphorus, iodine, chlorine, selenium and chromium.
The whey protein powder is hydrolyzed whey protein powder, and the protein content is more than 75%.
The vegetable oil is one or more of rapeseed oil, sunflower seed oil, palm oil, linseed oil and medium-chain triglyceride, wherein MCT: the weight ratio of LCT is 1: 1.
the MCT is medium chain triglyceride and the LCT is long chain triglyceride.
The preferable composition comprises the following raw materials in parts by weight: 22 parts of hydrolyzed whey protein, 23 parts of vegetable oil, 45 parts of maltodextrin, 3 parts of galacto-oligosaccharide, 1 part of arginine, 2 parts of glutamine, 3.5 parts of compound mineral substance, 0.35 part of compound vitamin and 0.06 part of stevioside.
The composition can be used for preparing product for improving malnutrition of patients with liver diseases.
The composition can be made into special medical food.
The preparation method of the special medical food comprises the following steps:
a. sieving the raw materials with 20 mesh sieve;
b. preparing materials: stevioside diluent powder: taking stevioside, and completely mixing with 0.1-1 part of maltodextrin; compound vitamin dilution powder: taking the compound vitamin, and completely mixing the compound vitamin with 2.8-4.2 parts of maltodextrin;
c. putting galacto-oligosaccharide, compound mineral, arginine, glutamine and stevioside diluted powder into a mixer to be completely mixed to obtain mixed powder 1;
d. mixing vegetable oil, vitamin complex diluent powder and the mixed powder 1, and uniformly mixing to obtain mixed powder 2;
e. and (3) completely mixing the residual maltodextrin with the mixed powder 2, and packaging to obtain the maltodextrin.
The sources of the raw materials and auxiliary materials are shown in the table 1.
TABLE 1 sources of the raw and auxiliary materials of the present invention
In order to improve the problem of insufficient protein of patients, hydrolyzed whey protein is particularly selected, and the whey protein is rich in small molecular peptides, complete in amino acids, reasonable in proportion, easy to absorb by a human body quickly, capable of reducing the burden of the liver and capable of effectively correcting the negative nitrogen balance of patients with liver diseases; secondly, the composition can promote the synthesis of skeletal muscle protein and prevent sarcopenia; finally, the protein is rich in branched chain amino acid, the branched chain amino acid can be metabolized by muscles, the concentration of the branched chain amino acid is increased, the liver burden is not increased, the branched chain amino acid and aromatic amino acid can competitively enter a blood brain barrier, and the prevention and treatment of hepatic encephalopathy are facilitated.
The invention adopts medium-chain glyceride and long-chain glyceride, and has reasonable proportion: and MCT: LCT ═ 1: 1; the MCT added can rapidly supply energy, correct complications such as fatty diarrhea and the like, and ensure the metabolism of essential fatty acid and the absorption of fat-soluble vitamins under the condition of hepatic insufficiency.
The invention strengthens fat-soluble vitamin A, D, K, vitamin B, calcium, iron, selenium and other minerals, and improves the deficiency of trace elements caused by liver dysfunction of hepatopaths. Particularly, by adding trivalent chromium, the insulin sensitivity can be effectively improved, so that the regulation of blood sugar is achieved.
The galactooligosaccharides with strong probiotic capability are added, so that the intestinal microorganisms are added, the intestinal peristalsis is promoted, and the ammonia is discharged.
The invention particularly adds glutamine to prevent hepatic encephalopathy; arginine can promote ornithine circulation and reduce blood ammonia.
The invention relates to a formula food with special medical application designed for the population of patients with liver diseases, which is prepared by adding vitamins, minerals or other nutritional ingredients into whey protein, vegetable oil, amino acid and the like and processing the whey protein, the vegetable oil, the amino acid and the like by physical means to meet the requirements of patients with liver diseases with malnutrition or nutritional risks on various nutritional ingredients, and further researches show that the formula food has good improvement effect on the patients with diabetes.
The composition is an organic composition, is an organic whole obtained by a plurality of creative tests in clinical research, is not simply added and combined, has effects on improving the nutritional status of patients with liver diseases and promoting liver recovery, and is also effective on patients with combined diabetes through creative test 1, namely the composition is not simply added but is an organic composition obtained through creative tests.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The technical solutions of the present invention are described below with specific examples, but the scope of the present invention is not limited thereto.
The embodiments described in this specification are merely illustrative of implementations of the inventive concept and the scope of the present invention should not be considered limited to the specific forms set forth in the embodiments but rather by the equivalents thereof as may occur to those skilled in the art upon consideration of the present inventive concept. While the following embodiments of the invention have been described, the invention is not limited to the specific embodiments and applications described above, which are intended to be illustrative, instructive, and not limiting. Those skilled in the art, having the benefit of this disclosure, may effect numerous modifications thereto without departing from the scope of the invention as defined by the appended claims.
The following tests are conclusion tests of research personnel based on multiple creative tests and on the technical scheme to be protected by the invention. In the quantitative tests in the following examples, three replicates were set, and the data are the mean or the mean ± standard deviation of the three replicates.
The following experiments were performed by the applicant's assigned Longyu Yao (Beijing) science and technology, Inc.
Test 1
Influence on liver damage caused by diabetes
Test groups:
test 1 group: 22g of hydrolyzed whey protein, rapeseed oil, sunflower seed oil, 23g of medium chain triglyceride (MCT: LCT weight ratio is 1: 1), 45g of maltodextrin, 3g of galacto-oligosaccharide, 1g of arginine, 2g of glutamine, 3.5g of compound mineral, 0.35g of compound vitamin and 0.06g of stevioside; mixing completely.
Test 2 groups: 45g of maltodextrin, 3g of galacto-oligosaccharide, 1g of arginine, 2g of glutamine, 3.5g of compound mineral, 0.35g of compound vitamin and 0.06g of stevioside; mixing completely.
The test method comprises the following steps: SD male rats with the weight of 200 +/-10 g are taken, experimental animals are always raised in a clean animal room, the conditions of constant temperature of 25 ℃ and constant humidity of 70% are stable, and the light and shade alternation is kept for 12 hours. After the experimental rats are fed with the basic feed for 7 days for adaptive feeding, 15 fasting (without water prohibition) animals are randomly selected for 12 hours, and fasting blood glucose is measured to serve as the basic blood glucose value of the animals in the batch. Then randomly classifying into cages, marking and weighing, and classifying into a normal control group and a model group. Feeding normal feed to a normal control group, feeding high-fat high-sugar feed to a model group (the formula of the high-fat high-sugar feed comprises 50% of basal feed, 20% of white granulated sugar, 16% of lard, 11% of casein, 1% of gelatin, 1% of cholesterol, 0.5% of cholate, 0.5% of mineral matter, 0.5% of vitamin, and fasting (without water) for 12h after 4 weeks, dissolving STZ in a sodium citrate-citric acid buffer solution with sterile pH of 4.2-4.5 and 0.1mol/L, wherein the injection concentration of the solution is 0.1g/L, injecting STZ (streptozotocin) 30mg/kg once per body weight into the abdominal cavity of a model group rat, measuring blood sugar after fasting (without water) for 12h after 7 days by injecting an equal amount of the buffer solution once per body weight into the normal control group, and randomly grouping the rats with blood sugar value of more than 16.7mmol/L according to the fasting blood sugar level of the model rat, namely a model control group, each test group and a pioglitazone hydrochloride group, and the experimental stage is started. During the period, the experimental animals are ensured to freely drink and eat water, and the mental status, the activity, the diet, the drinking water and the body hair color condition are observed every day. Feeding high-fat and high-sugar feed and distilled water to a model control group, feeding 3g/kg of a product to each test group by intragastric administration, feeding the high-fat and high-sugar feed, feeding 1.5mg/kg of pioglitazone hydrochloride by intragastric administration after 30 minutes, continuously taking 28 days, taking blood from a tail end vein after fasting (without water prohibition) for 12 hours after 28 days, and measuring the fasting blood glucose value by a glucometer; after the rats were sacrificed, organ index was measured, alanine Aminotransferase (ALT) and aspartate Aminotransferase (AST) were measured according to the kit instructions.
And (3) test results: see table.
TABLE 2 Effect on fasting plasma glucose in rats
Note: p <0.01 compared to normal control group, # P <0.05 compared to model control group.
The test summary is as follows: the above tests show that the blood sugar drop value is more after the composition and the pioglitazone hydrochloride are co-administered to the diabetic rats, which fully indicates that the composition is suitable for the diabetic patients.
TABLE 3 Effect on rat organs
Note: p <0.01 compared to normal control group; # P <0.01 and # P <0.05 compared to model control.
And (4) test conclusion: after the composition and the pioglitazone hydrochloride are simultaneously administered to diabetic rats, the body weight ratio model group is obviously increased, and the composition and the pioglitazone hydrochloride have obvious protective effect on liver injury and kidney injury.
TABLE 4 Effect on ALT and AST in rat serum
Note: p <0.01 compared to normal control group; # P <0.01 and # P <0.05 compared to model control.
The test summary is as follows: after the composition and the pioglitazone hydrochloride are simultaneously administered to rats, the composition has a good protective effect on liver injury.
Preparation examples
Example 1
2000g of whey protein, 1000g of vegetable oil, 4000g of maltodextrin, 10g of galacto-oligosaccharide, 10g of arginine, 10g of glutamine, 280g of compound mineral, 28g of compound vitamin and 1g of sweetening agent stevioside.
Wherein the vitamin complex comprises vitamin A, vitamin D, vitamin E, vitamin K, and vitaminsB1Vitamin B2Vitamin B6Vitamin B12Nicotinic acid, folic acid, pantothenic acid, vitamin C, biotin and taurine.
Wherein the compound mineral comprises sodium, potassium, copper, magnesium, ferrum, zinc, manganese, calcium, phosphorus, iodine, chlorine, selenium and chromium.
The whey protein powder is hydrolyzed whey protein powder, and the protein content is more than 75%.
Wherein the vegetable oil is sunflower oil, linseed oil and medium chain triglycerides, wherein MCT: the weight ratio of LCT is 1: 1.
the preparation method comprises the following steps:
a. sieving the raw materials with 20 mesh sieve;
b. preparing materials: stevioside diluent powder: taking stevioside, and completely mixing with 10g of maltodextrin; compound vitamin dilution powder: mixing the compound vitamin with 280g of maltodextrin completely;
c. putting galacto-oligosaccharide, compound mineral, arginine, glutamine and stevioside diluted powder into a mixer to be completely mixed to obtain mixed powder 1;
d. mixing vegetable oil, vitamin complex diluent powder and the mixed powder 1, and uniformly mixing to obtain mixed powder 2;
e. and (3) completely mixing the residual maltodextrin with the mixed powder 2, and packaging to obtain the maltodextrin.
Example 2
3000g of whey protein, 3000g of vegetable oil, 6000g of maltodextrin, 300g of galacto-oligosaccharide, 200g of arginine, 200g of glutamine, 420g of compound mineral, 42g of compound vitamin and 10g of sweetening agent stevioside.
Wherein the vitamin complex comprises vitamin A, vitamin D, vitamin E, vitamin K, and vitamin B1Vitamin B2Vitamin B6Vitamin B12Nicotinic acid, folic acid, pantothenic acid, vitamin C, biotin and taurine.
Wherein the compound mineral comprises sodium, potassium, copper, magnesium, ferrum, zinc, manganese, calcium, phosphorus, iodine, chlorine, selenium and chromium.
The whey protein powder is hydrolyzed whey protein powder, and the protein content is more than 75%.
Wherein the vegetable oil is palm oil, rapeseed oil and medium chain triglycerides, wherein MCT: the weight ratio of LCT is 1: 1.
the preparation method comprises the following steps:
a. sieving the raw materials with 20 mesh sieve;
b. preparing materials: stevioside diluent powder: taking stevioside, and completely mixing the stevioside with 100g of maltodextrin; compound vitamin dilution powder: mixing the compound vitamin with 420g of maltodextrin completely;
c. putting galacto-oligosaccharide, compound mineral, arginine, glutamine and stevioside diluted powder into a mixer to be completely mixed to obtain mixed powder 1;
d. mixing vegetable oil, vitamin complex diluent powder and the mixed powder 1, and uniformly mixing to obtain mixed powder 2;
e. and (3) completely mixing the residual maltodextrin with the mixed powder 2, and packaging to obtain the maltodextrin.
Example 3
2200g of hydrolyzed whey protein, 2300g of vegetable oil, 4500g of maltodextrin, 300g of galacto-oligosaccharide, 100g of arginine, 200g of glutamine, 350g of compound mineral, 35g of compound vitamin and 6g of stevioside.
Wherein the vitamin complex comprises vitamin A, vitamin D, vitamin E, vitamin K, and vitamin B1Vitamin B2Vitamin B6Vitamin B12Nicotinic acid, folic acid, pantothenic acid, vitamin C, biotin and taurine.
Wherein the compound mineral comprises sodium, potassium, copper, magnesium, ferrum, zinc, manganese, calcium, phosphorus, iodine, chlorine, selenium and chromium.
The whey protein powder is hydrolyzed whey protein powder, and the protein content is more than 75%.
Wherein the vegetable oil is rapeseed oil, sunflower seed oil and medium chain triglycerides, wherein MCT: the weight ratio of LCT is 1: 1.
the preparation method comprises the following steps:
a. sieving the raw materials with 20 mesh sieve;
b. preparing materials: stevioside diluent powder: taking stevioside, and completely mixing the stevioside with 60g of maltodextrin; compound vitamin dilution powder: taking the compound vitamin, and completely mixing the compound vitamin with 350g of maltodextrin;
c. putting galacto-oligosaccharide, compound mineral, arginine, glutamine and stevioside diluted powder into a mixer to be completely mixed to obtain mixed powder 1;
d. mixing vegetable oil, vitamin complex diluent powder and the mixed powder 1, and uniformly mixing to obtain mixed powder 2;
e. and (3) completely mixing the residual maltodextrin with the mixed powder 2, and packaging to obtain the maltodextrin.
Example 4
2305g of hydrolyzed whey protein, 2405g of vegetable oil, 4605g of maltodextrin, 315g of galacto-oligosaccharide, 110g of arginine, 205g of glutamine, 365g of compound mineral, 38g of compound vitamin and 6.6g of stevioside.
Wherein the vitamin complex comprises vitamin A, vitamin D, vitamin E, vitamin K, and vitamin B1Vitamin B2Vitamin B6Vitamin B12Nicotinic acid, folic acid, pantothenic acid, vitamin C, biotin and taurine.
Wherein the compound mineral comprises sodium, potassium, copper, magnesium, ferrum, zinc, manganese, calcium, phosphorus, iodine, chlorine, selenium and chromium.
The whey protein powder is hydrolyzed whey protein powder, and the protein content is more than 75%.
Wherein the vegetable oil is linseed oil, palm oil and medium chain triglycerides, wherein MCT: the weight ratio of LCT is 1: 1.
the preparation method comprises the following steps:
a. sieving the raw materials with 20 mesh sieve;
b. preparing materials: stevioside diluent powder: taking stevioside, and completely mixing the stevioside with 66g of maltodextrin; compound vitamin dilution powder: taking the compound vitamin, and completely mixing the compound vitamin with 380g of maltodextrin;
c. putting galacto-oligosaccharide, compound mineral, arginine, glutamine and stevioside diluted powder into a mixer to be completely mixed to obtain mixed powder 1;
d. mixing vegetable oil, vitamin complex diluent powder and the mixed powder 1, and uniformly mixing to obtain mixed powder 2;
e. and (3) completely mixing the residual maltodextrin with the mixed powder 2, and packaging to obtain the maltodextrin.
Example 5
Hydrolyzed whey protein 2035 g, vegetable oil 2395g, maltodextrin 4410g, galacto-oligosaccharide 325g, arginine 90g, glutamine 215g, compound mineral 340g, compound vitamin 38g and stevioside 6 g.
Wherein the vitamin complex comprises vitamin A, vitamin D, vitamin E, vitamin K, and vitamin B1Vitamin B2Vitamin B6Vitamin B12Nicotinic acid, folic acid, pantothenic acid, vitamin C, biotin and taurine.
Wherein the compound mineral comprises sodium, potassium, copper, magnesium, ferrum, zinc, manganese, calcium, phosphorus, iodine, chlorine, selenium and chromium.
The whey protein powder is hydrolyzed whey protein powder, and the protein content is more than 75%.
Wherein the vegetable oil is rapeseed oil, sunflower seed oil and medium chain triglycerides, wherein MCT: the weight ratio of LCT is 1: 1.
the preparation method comprises the following steps:
a. sieving the raw materials with 20 mesh sieve;
b. preparing materials: stevioside diluent powder: taking stevioside, and completely mixing the stevioside with 60g of maltodextrin; compound vitamin dilution powder: taking the compound vitamin, and completely mixing the compound vitamin with 380g of maltodextrin;
c. putting galacto-oligosaccharide, compound mineral, arginine, glutamine and stevioside diluted powder into a mixer to be completely mixed to obtain mixed powder 1;
d. mixing vegetable oil, vitamin complex diluent powder and the mixed powder 1, and uniformly mixing to obtain mixed powder 2;
e. and (3) completely mixing the residual maltodextrin with the mixed powder 2, and packaging to obtain the maltodextrin.
Comparative example 1
200g of hydrolyzed whey protein, 2300g of vegetable oil, 4500g of maltodextrin, 300g of galacto-oligosaccharide, 200g of glutamine, 350g of compound mineral substance, 35g of compound vitamin and 6g of stevioside.
Wherein the vitamin complex comprises vitamin A, vitamin D, vitamin E, vitamin K, and vitamin B1Vitamin B2Vitamin B6Vitamin B12Nicotinic acid, folic acid, pantothenic acid, vitamin C, biotin and taurine.
Wherein the compound mineral comprises sodium, potassium, copper, magnesium, ferrum, zinc, manganese, calcium, phosphorus, iodine, chlorine, selenium and chromium.
The whey protein powder is hydrolyzed whey protein powder, and the protein content is more than 75%.
Wherein the vegetable oil is rapeseed oil, sunflower seed oil and medium chain triglycerides, wherein MCT: the weight ratio of LCT is 1: 1.
the preparation method comprises the following steps:
a. sieving the raw materials with 20 mesh sieve;
b. preparing materials: stevioside diluent powder: taking stevioside, and completely mixing the stevioside with 60g of maltodextrin; compound vitamin dilution powder: taking the compound vitamin, and completely mixing the compound vitamin with 350g of maltodextrin;
c. putting galacto-oligosaccharide, compound mineral, glutamine and stevioside diluted powder into a mixer to be completely mixed to obtain mixed powder 1;
d. mixing vegetable oil, vitamin complex diluent powder and the mixed powder 1, and uniformly mixing to obtain mixed powder 2;
e. and (3) completely mixing the residual maltodextrin with the mixed powder 2, and packaging to obtain the maltodextrin.
Test 2
Protection effect on acute alcoholic liver injury of rat
Test compositions: example 3 and comparative example 1.
The test method comprises the following steps: the SPF-grade male SD rat of 6-8 weeks old has the body mass of 180-. From day 15, the composition was administered 1h later for the remaining groups except for the normal control group to which distilled water and maintenance diet were administered, and then the composition was administered 2 times with 50% ethanol gavage, 2 molding intervals of 6h, and high-fat diet feeding was continued for 7d, in order to show successful molding of the clinical manifestations and pathological changes of ALD: (1) changes in animal behavior occurred: listlessness, inappetence, loose stool, fluffy and lusterless fur, unstable walking, mouth scratching of the front paw and rigid action; (2) liver function index abnormality: the AST and ALT levels of the serum are obviously higher than those of a normal control group; (3) pathological dissection of animals: the liver surface has the changes of spots, swelling and the like; (4) pathological section: inflammatory infiltration of liver tissue or accumulation of fat droplets in hepatocytes, etc.
Fasting without water for 16h after the last model building, taking blood from abdominal aorta, separating serum, and measuring AST and ALT levels with full-automatic biochemical analyzer.
Before the rat is sacrificed, the mental state, the food intake, the excrement and urine, the body hair, the activity condition and the like of the rat are observed and recorded, the mass of the rat body is weighed and recorded, and the liver coefficient is calculated.
And (3) test results:
(1) the normal control group rats have no abnormal change in general conditions, the model group rats have gradually reduced food intake and water intake, and the phenomena of inappetence, loose stool, fluffy and lusterless fur, listlessness, unstable walking, mouth scratching of front claws, dull movements and the like begin to appear. The rats in the group of example 3 are generally better than the rats in the model group. The comparative example 1 group was observed to be inferior to the non-example 3 group.
(2) The influence on the body quality, liver index and serum AST and ALT levels of rats with acute alcoholic liver injury is shown in Table 5.
TABLE 5 Effect on body quality, liver index and serum AST and ALT levels in rats with acute alcoholic liver injury
Note: p <0.01, P <0.05 was compared to model groups.
And (4) test conclusion: the tests show that the composition has good protective effect on liver injury, can obviously improve weight, appetite, activity and the like, and test data show that the composition has extremely lower liver injury than a model group, and the protective effect on liver injury is reduced after the dosage of hydrolyzed whey protein is reduced and arginine is removed, so that the composition is an organic whole.
Claims (9)
1. The composition is characterized by comprising the following raw materials in parts by weight: 20-30 parts of whey protein, 10-30 parts of vegetable oil, 40-60 parts of maltodextrin, 0.1-3 parts of galacto-oligosaccharide, 0.1-2 parts of arginine, 0.1-2 parts of glutamine, 2.8-4.2 parts of compound mineral, 0.28-0.42 part of compound vitamin and 0.01-0.1 part of sweetening agent stevioside.
2. A composition according to claim 1, wherein said vitamin complex comprises vitamin A, vitamin D, vitamin E, vitamin K, vitamin B1Vitamin B2Vitamin B6Vitamin B12Nicotinic acid, folic acid, pantothenic acid, vitamin C, biotin and taurine.
3. A composition according to claim 1, wherein said complex minerals comprise sodium, potassium, copper, magnesium, iron, zinc, manganese, calcium, phosphorus, iodine, chlorine, selenium, chromium.
4. A composition as claimed in claim 1 wherein the whey protein powder is a hydrolyzed whey protein powder with a protein content > 75%.
5. A composition according to claim 1 wherein the vegetable oil is canola oil, sunflower oil, palm oil, linseed oil and medium chain triglycerides, wherein MCT: the weight ratio of LCT is 1: 1.
6. the composition according to claim 1, which comprises the following raw materials in parts by weight: 22 parts of hydrolyzed whey protein, 23 parts of vegetable oil, 45 parts of maltodextrin, 3 parts of galacto-oligosaccharide, 1 part of arginine, 2 parts of glutamine, 3.5 parts of compound mineral substance, 0.35 part of compound vitamin and 0.06 part of stevioside.
7. A composition according to any one of claims 1 to 6, characterized in that it is used for the preparation of a product for improving the malnutrition in patients with liver diseases.
8. A composition according to any one of claims 1 to 6, characterised in that it is prepared as a food for special medical use.
9. The composition of claim 8, wherein the food product is prepared by a method comprising:
a. sieving the raw materials with 20 mesh sieve;
b. preparing materials: stevioside diluent powder: taking stevioside, and completely mixing with 0.1-1 part of maltodextrin; compound vitamin dilution powder: taking the compound vitamin, and completely mixing the compound vitamin with 2.8-4.2 parts of maltodextrin;
c. putting galacto-oligosaccharide, compound mineral, arginine, glutamine and stevioside diluted powder into a mixer to be completely mixed to obtain mixed powder 1;
d. mixing vegetable oil, vitamin complex diluent powder and the mixed powder 1, and uniformly mixing to obtain mixed powder 2;
e. and (3) completely mixing the residual maltodextrin with the mixed powder 2, and packaging to obtain the maltodextrin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010112209.2A CN111329044A (en) | 2020-02-24 | 2020-02-24 | Composition for recovering patients with liver diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010112209.2A CN111329044A (en) | 2020-02-24 | 2020-02-24 | Composition for recovering patients with liver diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111329044A true CN111329044A (en) | 2020-06-26 |
Family
ID=71173913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010112209.2A Pending CN111329044A (en) | 2020-02-24 | 2020-02-24 | Composition for recovering patients with liver diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111329044A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703062A (en) * | 1984-01-16 | 1987-10-27 | Baxter Travenol Laboratories, Inc. | Parenteral nutrition with medium and long chain triglycerides |
| CN104082656A (en) * | 2014-06-12 | 2014-10-08 | 广东省农业科学院蚕业与农产品加工研究所 | Nutrient meal suitable for patient with liver disease and manufacturing method thereof |
| CN106605908A (en) * | 2016-05-27 | 2017-05-03 | 韶关邦世迪健康实业有限公司 | Fully nutritional formula product with special medical purposes for liver diseases |
| CN106722937A (en) * | 2016-11-25 | 2017-05-31 | 四川大学 | A kind of hepatopathy non-whole nutritional formula food, preparation method and application |
| CN109198625A (en) * | 2017-06-30 | 2019-01-15 | 况代武 | A kind of short peptide type nutritional food formula |
-
2020
- 2020-02-24 CN CN202010112209.2A patent/CN111329044A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703062A (en) * | 1984-01-16 | 1987-10-27 | Baxter Travenol Laboratories, Inc. | Parenteral nutrition with medium and long chain triglycerides |
| CN104082656A (en) * | 2014-06-12 | 2014-10-08 | 广东省农业科学院蚕业与农产品加工研究所 | Nutrient meal suitable for patient with liver disease and manufacturing method thereof |
| CN106605908A (en) * | 2016-05-27 | 2017-05-03 | 韶关邦世迪健康实业有限公司 | Fully nutritional formula product with special medical purposes for liver diseases |
| CN106722937A (en) * | 2016-11-25 | 2017-05-31 | 四川大学 | A kind of hepatopathy non-whole nutritional formula food, preparation method and application |
| CN109198625A (en) * | 2017-06-30 | 2019-01-15 | 况代武 | A kind of short peptide type nutritional food formula |
Non-Patent Citations (1)
| Title |
|---|
| 杨先芬等: "精氨酸强化肠外营养在肝硬化门静脉高压症术后应用研究", 《肝胆外科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tang et al. | Ingestion of whey hydrolysate, casein, or soy protein isolate: effects on mixed muscle protein synthesis at rest and following resistance exercise in young men | |
| JP4699901B2 (en) | Dietary additive with body fat metabolism function and combustion energy utilization function | |
| CN100415224C (en) | Compositions comprising fatty acids and amino acids | |
| KR101809172B1 (en) | Composition for preventing, improving or treating metabolic disease comprising Akkermansia muciniphila strain or its culture broth cultivated in medium without mucin as effective component | |
| ES2351701T3 (en) | USE OF ß-CRIPTOXANTINE. | |
| CN109222103B (en) | Muscle-building composition and health food | |
| CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
| CN110810845A (en) | Total nutrient formula powder with ketogenesis, fat reduction and sugar resistance functions and application thereof | |
| CN113924089A (en) | Compositions and methods for enhancing the musculoskeletal effects of one or more anabolic amino acids using one or more autophagy-inducing amino acids | |
| EP3010357B1 (en) | Administration of a food composition product | |
| JP2009286703A (en) | Body fat accumulation-improving agent and metabolic syndrome-improving agent containing d-tagatose as active ingredient | |
| KR20070113460A (en) | The health food composition for regulating weight | |
| CN103006709B (en) | Bee-pollen buccal tablet for preventing and treating alcoholic fatty liver | |
| WO2017191856A1 (en) | Antidiabetic effect of gypenoside 75 | |
| US20120058938A1 (en) | Nutritional composition inducing a postprandial endocrine response | |
| CN110447892A (en) | A kind of special medicine purposes amino acid pattern hepatopathy full nutrition formula food | |
| CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
| Lee et al. | The effect of swimming exercise and powdered-Salicornia herbacea L. ingestion on glucose metabolism in STZ-induced diabetic rats | |
| JP2021506231A (en) | Compositions and Methods That Use High Proteins for Inducing Autophagy | |
| KR20200016608A (en) | The health food composition for regulating weight | |
| WO2015009225A1 (en) | Food composition product | |
| JP4864064B2 (en) | Peptide having anti-diabetic action and use thereof | |
| CN111329044A (en) | Composition for recovering patients with liver diseases | |
| US11980214B2 (en) | Dietary fiber compositions with psyllium and methods of use | |
| CN108354080A (en) | A kind of preparation method of obesity phase special weight-reducing dog grain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 201, room 4, building 101, No. 1, 310018 Avenue, Hangzhou economic and Technological Development Zone, Zhejiang, China Applicant after: Zhejiang Heze Pharmaceutical Technology Co.,Ltd. Applicant after: HANGZHOU HEZE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 201, room 4, building 101, No. 1, 310018 Avenue, Hangzhou economic and Technological Development Zone, Zhejiang, China Applicant before: Hangzhou Zejian Pharmaceutical Technology Co.,Ltd. Applicant before: HANGZHOU HEZE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Room 201, building 4, No. 101, No. 1 Street, Qiantang New District, Hangzhou City, Zhejiang Province Applicant after: Zhejiang Heze Pharmaceutical Technology Co.,Ltd. Applicant after: HANGZHOU HEZE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 201, room 4, building 101, No. 1, 310018 Avenue, Hangzhou economic and Technological Development Zone, Zhejiang, China Applicant before: Zhejiang Heze Pharmaceutical Technology Co.,Ltd. Applicant before: HANGZHOU HEZE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200626 |
|
| RJ01 | Rejection of invention patent application after publication |